Phase Ii Study Of Recombinant Alpha-Interferon (Rifn Alpha) And Continuous-Infusion 5-Fluorouracil In Metastatic Breast Cancer

Twenty-six patients with metastatic breast cancer were offered a phase IT combination of recombinant a-interferon and continuous-infusion 5-fluorouracil (5-FU). 5-FU was administered at 750 mg/m(2) daily for 5 days as a continuous infusion acid recombinant interferon at 5 million U/m(2) subcutaneously days 1, 3, and 5 of each course. The courses were repeated every 14 days. Despite moderate nonmyelosuppressive toxicity, only two (8%) partial remissions were observed. In this schedule, the addition of recombinant alpha-interferon to conventional continuous-infusion 5-FU resulted in a response rate of 8%.